The global antibiotic susceptibility testing market size was valued at USD 4.18 billion in 2025 and is projected to grow from USD 4.41 billion in 2026 to USD 6.84 billion by 2034, registering a CAGR of 5.62% during the forecast period (2026-2034). North America dominated the antibiotic susceptibility testing market with a share of 41.07% in 2025.
Antibiotic susceptibility testing is a laboratory diagnostic procedure used to determine the effectiveness of antibiotics against bacterial infections. The testing includes disk diffusion, broth dilution, automated systems, and molecular methods. AST products include testing kits, reagents, culture media, and instruments used in hospitals and diagnostic laboratories. Diagnostic reagents fall under HSN Code 3822, while medical laboratory testing services are classified under SIC Code 8071.
The antibiotic susceptibility testing market demand is driven by increasing antimicrobial resistance and the need for targeted antibiotic treatment. Hospital laboratories are adopting automated testing systems and rapid diagnostic methods to improve treatment decisions, supporting antibiotic susceptibility testing market growth.
Download a Free Sample To learn more about this report,
Adoption of Expanded Antibiotic Testing Panels
The antibiotic susceptibility testing market analysis highlights increasing laboratory demand for testing panels covering broader antibiotic combinations. Clinical laboratories are adopting comprehensive susceptibility panels to assess resistance against multiple antibiotics in a single testing process. Manufacturers are developing flexible testing platforms that accommodate newly approved antibiotics and updated susceptibility breakpoints.
Preference for Direct Blood Culture Susceptibility Testing
Hospital laboratories are increasingly adopting rapid susceptibility testing directly from positive blood cultures. This approach reduces dependence on conventional bacterial subculturing and supports earlier antibiotic selection for bloodstream infections. bioMérieux's VITEK REVEAL system can deliver susceptibility results for Gram-negative bacteria in approximately 5.5 hours.
Supply chain disruptions are expected to have a moderate impact on the antibiotic susceptibility testing market share due to shortages of testing reagents, antibiotic discs, culture media, and laboratory consumables. The market is expected to experience a K-shaped recovery as established manufacturers with diversified supplier networks can restore operations faster. The market is projected to grow at a CAGR of 5.62%, but supply constraints could lower short-term growth by 1.0 percentage point to 4.62% under an illustrative disruption scenario. Improved reagent availability and stable distribution networks could support recovery toward 5.62%.
The antibiotic susceptibility testing market forecasts continued investment in rapid diagnostic technologies and automated testing systems. In May 2026, iFAST Diagnostics announced USD 6.7 million funding to support rapid AST commercialization, European regulatory approval, and US clinical development.
Prevalance of Antibiotic Resistant Bacterial Infections and Rising Adoption of Invasive Arterial Monitoring in High-Risk Surgeries Drives Market
Prevalence of antibiotic-resistant bacterial infections is strengthening demand for antibiotic susceptibility testing across hospitals and diagnostic laboratories. Antibiotic resistance in common pathogens such as Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus is increasing the need for accurate susceptibility assessment. Thus, the need for targeted antibiotic therapy supports demand for automated susceptibility testing systems and laboratory consumables.
Implementation of antimicrobial stewardship programs in hospitals is strengthening demand for antibiotic susceptibility testing. These programs encourage clinicians to use laboratory results for appropriate antibiotic selection and reduce unnecessary broad-spectrum treatment. The U.S. CDC's hospital stewardship framework recommends selective reporting of susceptibility results to guide antibiotic prescriptions.
High Automated Testing Costs and Frequent Susceptibility Breakpoint Revisions Restrain Market Expansion
Automated antibiotic susceptibility testing systems require substantial investment in laboratory equipment and ongoing maintenance. Additional expenditure on proprietary reagent cards and quality control materials increases testing costs. These financial barriers restrict the adoption of automated systems in resource-constrained healthcare facilities.
Regular revisions to antibiotic susceptibility breakpoints create operational challenges for clinical laboratories. Updated interpretation criteria require laboratories to review testing procedures and verify compatibility with existing instruments. Manufacturers also face additional technical requirements to maintain the clinical accuracy of susceptibility testing systems.
Microfluidic-Based Rapid Phenotypic Testing and Decentralized Antibiotic Susceptibility Testing Offers Growth Opportunities
Need for faster antibiotic treatment decisions in hospitals is encouraging investment in rapid phenotypic susceptibility testing. According to EUCAST, rapid susceptibility testing directly from positive blood cultures can provide results within 4–8 hours of incubation. This demand provides manufacturers with opportunities to commercialize microfluidic-based testing platforms, expand rapid testing portfolios, and secure contracts with hospital laboratories seeking faster diagnostic results.
Limited availability of microbiology laboratories in underserved regions presents expansion opportunities for antibiotic susceptibility testing manufacturers. Smaller hospitals and healthcare facilities often depend on centralized laboratories, creating demand for accessible and cost-effective testing solutions. Market players can target these facilities with portable susceptibility testing instruments, simplified workflows, and affordable consumables.
Consumables and reagents dominated the product segment with a share of 38.10% in 2025, owing to replacement of antibiotic discs and culture media. High volume of bacterial infection testing and recurring reagent requirements support consistent procurement across clinical laboratories.
Automated AST instruments are likely to witness a CAGR of 6.42% during the forecast period, driven by increasing laboratory automation and the demand for faster susceptibility results and standardized interpretation.
Request Customizationto receive a tailored report.
In 2025, antibacterial had a share of 64.20%, supported by high testing volume of bacterial infections. The increasing prevalence of multidrug-resistant infections and routine testing of clinical bacterial isolates are strengthening demand across hospital microbiology laboratories.
Antiviral AST is anticipated to record a growth rate of 6.27% during the forecast period, owing to increasing antiviral resistance monitoring. Growing demand for HIV resistance genotyping and personalized antiviral treatment is supporting the adoption of molecular resistance assays.
Clinical diagnostics dominated the application segment in 2025, accounting for a share of 71.50%. This dominance is driven by increasing demand for targeted antibiotic treatment. The rising demand for bloodstream infection testing and reliance on susceptibility reports for antibiotic selection are supporting diagnostic testing volumes.
Drug discovery and development is estimated to register a growth rate of 6.21% during the forecast period, owing to research into new antibiotics and drug molecules. The increased screening of resistant bacterial strains and demand for minimum inhibitory concentration assessments support segment growth.
Hospital laboratories led the end user segment with a share of 44.80% in 2025, driven by direct access to patient specimens and established microbiology infrastructure. In-house testing capabilities enable faster communication of susceptibility results, while close coordination with treating physicians supports timely antibiotic selection.
Contract research organizations will expand to 6.46% CAGR during the forecast period, supported by specialized antimicrobial testing expertise and cost-efficient research services. Pharmaceutical companies increasingly prefer CROs for access to validated testing protocols and specialized laboratory infrastructure without substantial capital investment.
Speak to an Analystto discuss market opportunities.
The North America antibiotic susceptibility testing market accounted for the largest regional share of 41.07% in 2025.
The U.S. Centers for Disease Control and Prevention operates the Antimicrobial Resistance Laboratory Network to detect emerging drug-resistant pathogens. The network provides specialized susceptibility testing for carbapenem-resistant Enterobacterales and other priority organisms. Hospital laboratories also use expanded antibiotic panels to guide treatment of difficult bacterial infections. The established reference laboratory infrastructure and growing need for resistance mechanism detection support demand for advanced susceptibility testing systems.
Canada's Public Health Agency operates the Antimicrobial Resistance Network (AMRNet) to collect susceptibility data from clinical and veterinary laboratories. The network supports standardized resistance monitoring across provincial healthcare systems. Canadian diagnostic laboratories contribute bacterial isolate data to improve regional resistance assessments.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific antibiotic susceptibility testing market is expected to grow at a CAGR of 7.43% during the forecast period, showcasing the fastest-growing regional market
A well-established antimicrobial resistance surveillance network is a key factor supporting China's antibiotic susceptibility testing market. The China Antimicrobial Resistance Surveillance System (CARSS) collects bacterial resistance data from hospitals to monitor resistance patterns and inform antibiotic prescribing practices. High testing volumes across tertiary hospitals create opportunities for automated susceptibility testing instruments and laboratory workflow solutions.
India's National Action Plan on Antimicrobial Resistance 2.0 emphasizes strengthening diagnostic stewardship and laboratory capacity across healthcare facilities. The government's focus on developing point-of-care diagnostics creates opportunities for rapid antibiotic susceptibility testing technologies. Private diagnostic chains are also positioned to benefit from growing demand for specialized microbiology services.
Advanced clinical laboratory capabilities and the growing elderly population influence antibiotic susceptibility testing demand in Japan. The high prevalence of age-related infections and hospital-acquired bacterial infections increases the importance of accurate antibiotic selection. Collaboration between healthcare facilities and external diagnostic laboratories supports access to specialized microbiology services.
Europe antibiotic susceptibility testing market is expected to experience a growth rate of 5.12% during the forecast period.
The UK's National Institute for Health and Care Excellence recognizes the potential of point-of-care susceptibility testing to improve antibiotic selection for urinary tract infections. Conventional laboratory testing can take several days, creating demand for faster diagnostic methods. NHS primary care services also rely on urine culture results to manage recurrent and complicated infections.
DART 2030 emphasizes appropriate antibiotic use through reliable laboratory diagnostics. The German National Antibiotic Susceptibility Testing Committee promotes EUCAST breakpoint standards for accurate resistance interpretation. German laboratories also follow standardized quality control procedures to maintain testing accuracy.
Latin America antibiotic susceptibility testing market will expand to 5.74% CAGR during the forecast period. Brazil participates in the Pan American Health Organization's ReLAVRA+ network, which promotes standardized susceptibility testing and laboratory quality assessment. Mexico's national reference laboratory also participates in regional resistance monitoring and standardized reporting of bacterial isolates. These initiatives support demand for susceptibility testing reagents and reliable diagnostic instruments across clinical microbiology laboratories.
Middle East & Africa antibiotic susceptibility testing market is expected to achieve a growth rate of 5.58% during the forecast period. Abu Dhabi's Department of Health requires participating healthcare facilities to report antimicrobial susceptibility testing results to the Abu Dhabi Public Health Center. South Africa's National Institute for Communicable Diseases provides reference susceptibility testing for resistant bacterial pathogens. Ethiopia's efforts to develop locally manufactured antibiotic testing discs also support affordable laboratory testing and reduced dependence on imported consumables.
The antibiotic susceptibility testing market competitive landscape is moderately consolidated, with competition comprising established diagnostic manufacturers, specialized microbiology companies, and emerging rapid-testing providers. Key players such as bioMérieux, Becton Dickinson, Thermo Fisher Scientific, Danaher, and Bio-Rad Laboratories are estimated to collectively account for approximately 55–60% of the global antibiotic susceptibility testing market share.
Established manufacturers compete through automated testing platforms, extensive reagent portfolios, laboratory integration capabilities, and global distribution networks. Emerging players in the antibiotic susceptibility testing market ecosystem focus on rapid phenotypic testing, microfluidic technologies, and direct-from-sample susceptibility analysis.
April 2026: Q-linea received U.S. FDA clearance for its expanded ASTar antimicrobial susceptibility testing panel.
April 2026: bioMérieux received U.S. FDA 510(k) clearance for its VITEK 2 AST-Streptococcus inducible clindamycin resistance test.
June 2025: bioMérieux announced the acquisition of Day Zero Diagnostics' assets to strengthen next-generation sequencing capabilities for rapid bacterial identification and antibiotic susceptibility testing.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Adult Pediatric Hemoconcentrators Market Size, Opportunities, 2034
Handheld Backscatter X-Ray Devices Market Size, Share, Growth, 2034
Arterial Cannula Market Size, Forecast, Demand, Opportunities, 2034
Ultrasound Devices Market Size, Share, Growth, Analysis, 2034
Catheter Directed Thrombolysis Market Size, Forecast, Demand, Opportunities, 2034
Breast Biopsy Device Market Size, Forecast, Opportunities, 2034
We are featured on:
sales@straitsresearch.com